156 related articles for article (PubMed ID: 31212025)
21. The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer.
Atguden Z; Yildiz A; Aksut H; Yalcin SE; Yalcin Y; Uysal D; Yetimalar H
Asian Pac J Cancer Prev; 2016; 17(2):497-501. PubMed ID: 26925634
[TBL] [Abstract][Full Text] [Related]
22. The Value of Papanicolaou Tests in the Diagnosis of Endometrial Carcinoma: A Large Study Cohort From an Academic Medical Center.
Serdy K; Yildiz-Aktas I; Li Z; Zhao C
Am J Clin Pathol; 2016 Mar; 145(3):350-4. PubMed ID: 27124917
[TBL] [Abstract][Full Text] [Related]
23. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Xu MJ; Chu C; Rubin S; Lin LL
Am J Clin Oncol; 2017 Dec; 40(6):598-604. PubMed ID: 26237194
[TBL] [Abstract][Full Text] [Related]
24. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis.
Carrara L; Gadducci A; Landoni F; Maggino T; Scambia G; Galletto L; Lissoni AA; Fuso L; Zola P; Sartori E
Int J Gynecol Cancer; 2012 Jul; 22(6):1013-9. PubMed ID: 22706226
[TBL] [Abstract][Full Text] [Related]
25. [Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma].
Wang Q; Hong L; Wang JL; Yue MG; Li HB; Li Y
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):300-3. PubMed ID: 20510085
[TBL] [Abstract][Full Text] [Related]
26. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.
Sartori E; Pasinetti B; Carrara L; Gambino A; Odicino F; Pecorelli S
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S241-7. PubMed ID: 17826824
[TBL] [Abstract][Full Text] [Related]
27. The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
Touhami O; Grégoire J; Renaud MC; Sebastianelli A; Grondin K; Plante M
Gynecol Oncol; 2018 Mar; 148(3):485-490. PubMed ID: 29290489
[TBL] [Abstract][Full Text] [Related]
28. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma.
Zhang Y; Qu X; Qu PP
J BUON; 2016; 21(6):1491-1495. PubMed ID: 28039713
[TBL] [Abstract][Full Text] [Related]
29. Abnormal cervical cytology: a risk factor for endometrial cancer recurrence.
Brown AK; Gillis S; Deuel C; Angel C; Glantz C; Dubeshter B
Int J Gynecol Cancer; 2005; 15(3):517-22. PubMed ID: 15882179
[TBL] [Abstract][Full Text] [Related]
30. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
[TBL] [Abstract][Full Text] [Related]
31. Preoperative cervical cytology in endometrial carcinoma and its clinicopathologic relevance.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H; Yamasaki F
Gynecol Oncol; 1999 Mar; 72(3):273-7. PubMed ID: 10053095
[TBL] [Abstract][Full Text] [Related]
32. The long-term survival of women with surgical stage II endometrioid type endometrial cancer.
Ayhan A; Taskiran C; Celik C; Yuce K
Gynecol Oncol; 2004 Apr; 93(1):9-13. PubMed ID: 15047207
[TBL] [Abstract][Full Text] [Related]
33. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
[TBL] [Abstract][Full Text] [Related]
34. Recurrence patterns and surveillance for patients with early stage endometrial cancer.
Salani R; Nagel CI; Drennen E; Bristow RE
Gynecol Oncol; 2011 Nov; 123(2):205-7. PubMed ID: 21820709
[TBL] [Abstract][Full Text] [Related]
35. Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review.
Esselen KM; Boruta DM; del Carmen M; Schorge JO; Goodman A; Growdon WB
Int J Gynecol Cancer; 2011 Aug; 21(6):1078-83. PubMed ID: 21633304
[TBL] [Abstract][Full Text] [Related]
36. Stage 1C grade 3 endometrial cancer: the KK Hospital gynaecological oncology group experience.
Siow TR; Yeo MC; Khoo-Tan HS; Yap SP; Soong YL; Chua EJ; Soh LT; Lim YK; Chia YN; Yam KL
Int J Gynecol Cancer; 2010 Dec; 20(9):1557-62. PubMed ID: 21119369
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer.
Han KH; Park NH; Kim HS; Chung HH; Kim JW; Song YS
Gynecol Oncol; 2014 Aug; 134(2):293-6. PubMed ID: 24854062
[TBL] [Abstract][Full Text] [Related]
38. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
Cooper AL; Dornfeld-Finke JM; Banks HW; Davey DD; Modesitt SC
Obstet Gynecol; 2006 Jan; 107(1):71-6. PubMed ID: 16394042
[TBL] [Abstract][Full Text] [Related]
39. Significance of atypical endometrial cells in women younger than 40 years of age.
Yuan L; Biscotti CV; Zhu H; Booth CN; Abdul-Karim FW; Zhang Y
J Am Soc Cytopathol; 2020; 9(1):33-37. PubMed ID: 31353256
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
